PTPN6 and hepatocellular carcinoma: Other kinase inhibitors, such as nintedanib [161], regorafenib [162], and dovitinib [163], induced significant anti-HCC activity independent of kinase inhibition activity by relieving auto-inhibition of SHP-1 to activate its activity.